Unraveling the Role of Fibroblasts, FGF5 and FGFR2 in HER2-targeted Therapies Resistance and Tumor Progression

Overview

Journal Oncotarget

Specialty Oncology

Date 2020 Dec 21

PMID 33346249

Citations 1

Authors

Paloma Bragado

Patricia Fernandez-Nogueira

Neus Carbo

Pere Gascon

Affiliations

Soon will be listed here.

Citing Articles

Multi-Omics Characterization of Genome-Wide Abnormal DNA Methylation Reveals FGF5 as a Diagnosis of Nasopharyngeal Carcinoma Recurrence After Radiotherapy.

Long Z, Ding R, Quan T, Xu R, Huang Z, Wei D Biomolecules. 2025; 15(2).

PMID: 40001587 PMC: 11853517. DOI: 10.3390/biom15020283.

Proteomic profiling identifies biomarkers of COVID-19 severity.

Harriott N, Ryan A Heliyon. 2024; 10(1):e23320.

PMID: 38163173 PMC: 10755324. DOI: 10.1016/j.heliyon.2023.e23320.

References

Zervantonakis I, Poskus M, Scott A, Selfors L, Lin J, Dillon D . Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. Proc Natl Acad Sci U S A. 2020; 117(28):16500-16508. PMC: 7368275. DOI: 10.1073/pnas.2000648117. View

Merz V, Zecchetto C, Simionato F, Cavaliere A, Casalino S, Pavarana M . A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. Ther Adv Med Oncol. 2020; 12:1758835920937889. PMC: 7346700. DOI: 10.1177/1758835920937889. View

Klemm F, Joyce J . Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2014; 25(4):198-213. PMC: 5424264. DOI: 10.1016/j.tcb.2014.11.006. View

Gascard P, Tlsty T . Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016; 30(9):1002-19. PMC: 4863733. DOI: 10.1101/gad.279737.116. View

Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacopuzzi S, Aprile G . An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients. Clin Cancer Res. 2016; 22(24):6164-6175. DOI: 10.1158/1078-0432.CCR-16-0178. View

Mao Y, Zhang Y, Qu Q, Zhao M, Lou Y, Liu J . Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells. Mol Biosyst. 2015; 11(4):1029-40. DOI: 10.1039/c4mb00710g. View

Hanker A, Garrett J, Estrada M, Moore P, Ericsson P, Koch J . HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res. 2017; 23(15):4323-4334. PMC: 5540793. DOI: 10.1158/1078-0432.CCR-16-2287. View

Bharadwaj U, Eckols T, Kolosov M, Kasembeli M, Adam A, Torres D . Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene. 2014; 34(11):1341-53. PMC: 4182178. DOI: 10.1038/onc.2014.72. View

Dieci M, Miglietta F, Griguolo G, Guarneri V . Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. Cancer Treat Rev. 2020; 88:102064. DOI: 10.1016/j.ctrv.2020.102064. View

10.

Marusyk A, Tabassum D, Janiszewska M, Place A, Trinh A, Rozhok A . Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016; 76(22):6495-6506. PMC: 5344673. DOI: 10.1158/0008-5472.CAN-16-1457. View

11.

Cazet A, Hui M, Elsworth B, Wu S, Roden D, Chan C . Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun. 2018; 9(1):2897. PMC: 6057940. DOI: 10.1038/s41467-018-05220-6. View

12.

Fernandez-Nogueira P, Mancino M, Fuster G, Lopez-Plana A, Jauregui P, Almendro V . Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation. Clin Cancer Res. 2019; 26(6):1432-1448. DOI: 10.1158/1078-0432.CCR-19-0353. View